Eli Lilly has announced positive topline Phase III results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycaemic control with diet and exercise alone.  

Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase III trial.  

The announcement follows news of Pfizer’s decision to discontinue development of its oral GLP-1 receptor agonist danuglipron. 

“ACHIEVE-1 is the first of seven Phase III studies examining the safety and efficacy of orforglipron across people with diabetes and obesity. We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year,” said David Ricks, Lilly Chair and CEO. “As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world.” 

In the first Phase III trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand. 

In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, which is below the American Diabetes Association’s (ADA) defined threshold for diabetes. 

In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs (7.9%) at the highest dose. 

The overall safety profile of orforglipron was consistent with the established GLP-1 class. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity.

Diana Spencer, Senior Digital Content Editor, DDW